Not finding it? Sign in to also search OpenAlex live.
-
Oral semaglutide and CV benefits in the SOUL trial: how do baseline or changes in HbA1c and BMI affect clinical outcomes?2026 The Journal of Clinical Endocrinology & Metabolism article Medicine Diabetes Treatment and Management Open access
Silvio E. Inzucchi, Rohana Abdul Ghani, John Eric Deanfield, M D Engelmann, G. Kees Hovingh, Ole Kleist Jeppesen, +16 more
1citations -
Unterschiede in HbA1c-senkender Wirkung und Hypoglykämierisiko zwischen Insulin glargin 300 E/ml (Gla-300) und Insulin degludec 100 E/ml (IDeg) je nach Nierenfunktion in der BRIGHT-Studie
Martin Haluzı́k, Athena Philis‐Tsimikas, Zsolt Bosnyák, Dirk Müller‐Wieland, Felipe Lauand, Lydie Melas‐Melt, +2 more
0citations -
Differenzen zwischen dem CGM-Parameter GMI und HbA1c: Ein Handlungsvorschlag der Kommission für Labordiagnostik in der Diabetologie2026 Diabetologie und Stoffwechsel article Medicine Diabetes, Cardiovascular Risks, and Lipoproteins
Erwin Schleicher, Dirk Müller‐Wieland, Matthias Nauck, Lutz Heinemann, Guido Freckmann
0citations -
Unterschiede bei der HbA1c-Senkung zwischen Insulin glargin 300 E / ml (Gla-300) und Insulin degludec 100 E / ml (IDeg-100) bei Typ-2-Diabetespatienten ≥ 70 Jahre in der BRIGHT-Studie
Dirk Müller‐Wieland, Bernard H. Charbonnel, V.R. Aroda, J Westerbakka, Felipe Lauand, Emmanuelle Boëlle, +3 more
0citations -
P49 How borderline HbA1c levels may potentially build a bridge between chronic idiopathic axonal polyneuropathy (CIAP) and diabetic polyneuropathy2020 Clinical Neurophysiology conference-abstract Medicine Botulinum Toxin and Related Neurological Disorders
Annabelle Ouwenbroek, Thorsten Hornemann, Jörg Bernhard Schulz, Burkhard Gess, Maike Franziska Dohrn
0citations -
Personal Glycation Factors and Calculated Hemoglobin A1c for Diabetes Management: Real-World Data from the Diabetes Prospective Follow-up (DPV) Registry2021 Diabetes Technology & Therapeutics article Medicine Diabetes Management and Research Open access cited by 1 patent
Yongjin Xu, Julia M. Grimsmann, Beate Karges, Sabine E. Hofer, Thomas Danne, Reinhard Walter Holl, +2 more
18citations -
Effects of data management system with online coaching intervention or usual care on glycemic control in patients with type 2 diabetes: a multicenter, randomized controlled trial
Marlo Verket, Larissa F. Buitkamp, Niveditha Daneeza Dinesh Kanna, Ralf J. Denger, Friedhelm Petry, Oliver Schubert-Olesen, +11 more
0citations -
Effects of coaching with data management system intervention or usual care on glycemic control in patients with type 2 diabetes: A multicentre, randomised controlled trial
Marlo Verket, Larissa F. Buitkamp, Niveditha Daneeza Dinesh Kanna, Andreas Thomas, Ralf J. Denger, Friedrich Wilhelm Petry, +14 more
0citations -
Gaps in Glycaemic Monitoring and Underuse of Cardioprotective Glucose-lowering Agents: Challenges of inpatient diabetes care identified by EFIM’s Diabesity Day Survey 20242025 European Journal of Internal Medicine article Medicine Hyperglycemia and glycemic control in critically ill and hospitalized patients Open access
Ann‐Kristin Porth, Burcu Sallarel, Dimitrios Patoulias, Dirk Müller‐Wieland, Dror Dicker, Il'ya Yur'evich Davidenko, +7 more
8citations -
Does Gender Influence the Effectiveness and Safety of Insulin Glargine 300 U/ml in Patients with Uncontrolled Type 2 Diabetes? Results from the REALI European Pooled Analysis
Pierre Gourdy, Riccardo C. Bonadonna, Nick Freemantle, Dı́dac Mauricio, Dirk Müller‐Wieland, Grégory Bigot, +3 more
7citations -
Effects of linagliptin vs glimepiride stratified by prior insulin secretagogue use in the cardiovascular outcome study of linagliptin versus glimepiride in type 2 diabetes (CAROLINA) trial
Darren K. McGuire, J Rosenstock, Odd-Erik Johansen, Bernard Zinman, Kamlesh K. Khunti, Michaela Mattheus, +3 more
1citations -
Impact of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: a SOUL post hoc analysis
Sharon L. Mulvagh, John E. Deanfield, Samuel Emerson, S E Inzucchi, Johannes F.E. Mann, Nikolaus Marx, +9 more
0citations -
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
Vlado Perkovic, Robert Daniel Toto, Mark Emmanuel Cooper, Johannes F.E. Mann, Julio Rosenstock, Darren K. McGuire, +11 more
63citations -
Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial
Martin Haluzı́k, ALICE Y.Y. CHENG, Dirk Müller‐Wieland, Jukka Westerbacka, Zsolt Bosnyák, Felipe Lauand, +4 more
31citations